The eye might be a small organ, but it plays a vital role in the way we lead our lives. This organ is also susceptible to various diseases, other than the common glaucoma and cataract we know. There are diseases related to the eye that are brought about by age.
Ophthotech Corporation is one of the companies that focus its resources in the development of therapeutics that are geared towards addressing diseases related to the eye, particularly those that occur at the back of the organ. It was in January 2007 that the company was incorporated. Today, it has its advanced product candidate, the Fovista, which is used in combination with anti-vascular endothelial growth factor (VEGF) drugs. It also has another product under development, the Zimura, which is a treatment for geographic atrophy.
It is in New York City that the business holds its corporate office. The business remains publicly traded on the NASDAQ and markets its common shares using the ticker symbol OPHT. It is listed as a component of the Wilshire 5000 Index.